PUBLISHER: Acute Market Reports | PRODUCT CODE: 1552375
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1552375
Muscle wasting disorders, characterized by the significant reduction of muscle mass and strength, have been the subject of increased medical attention over recent years. These conditions encompass a variety of diseases ranging from sarcopenia, typically related to aging, to neuromuscular disorders like muscular dystrophy. The muscle wasting disorders market is estimated to grow at a CAGR of 15.5% from 2024 to 2032.
Driver: Increasing Aging Population and Associated Sarcopenia
One of the primary drivers for the muscle wasting disorders market is the exponential rise in the global aging population. As the baby boomer generation enters the senior age bracket, the prevalence of sarcopenia - a muscle wasting condition closely associated with aging - has surged. According to the United Nations' report on World Population Aging, the number of individuals aged 60 years or older is expected to double by 2050. This demographic shift has led to an uptick in cases of sarcopenia. Compounded by the fact that muscle wasting exponentially increases the risk of physical disabilities, falls, fractures, and overall mortality, the healthcare industry's focus on combating this disorder has intensified. Treatment strategies ranging from hormone replacement therapies to strength training regimens have garnered attention, signifying the market's expansive potential.
Opportunity: Advancements in Genetic Therapies for Neuromuscular Disorders
The realm of genetic therapies has showcased promising results in addressing the root causes of certain muscle wasting disorders, especially those of a hereditary nature like muscular dystrophy. Recent case studies highlight instances where gene therapies have been successful in introducing or correcting specific genes, leading to improved muscle function and reduced disease progression. For instance, a publication in the New England Journal of Medicine detailed a gene therapy trial that demonstrated improved motor functions in children with a specific type of muscular dystrophy. As genetic research continues to unveil the underlying mutations causing these disorders, the opportunity to develop targeted therapies expands, potentially revolutionizing the treatment landscape.
Restraint: High Treatment Costs and Limited Accessibility
While advancements in treatment and management are promising, they come at a steep price. The costs associated with cutting-edge treatments, especially genetic therapies, are exorbitant. Many of these treatments are not universally covered by insurance, placing a significant financial burden on patients. Furthermore, the limited availability of specialized treatment centers, primarily in low-to-middle-income countries, restricts access to care. A study in the Journal of Clinical Medicine emphasized the significant disparities in the availability of neuromuscular disorder treatments across different regions, elucidating the market's challenges in achieving global reach.
Challenge: Variability in Clinical Presentation and Diagnostic Difficulties
Muscle wasting disorders present with a wide variability in clinical symptoms, often making early diagnosis challenging. Given that timely intervention is crucial to manage progression, this diagnostic delay can lead to compromised patient outcomes. Muscle biopsies, one of the gold standards in diagnosing certain muscle-wasting disorders, are invasive and might not always provide conclusive results. An article in the Muscle & Nerve journal highlighted instances where muscle biopsies yielded non-specific results, necessitating further diagnostic procedures. This variability not only prolongs the diagnostic journey but also amplifies the emotional and financial distress associated with these disorders.
Market Segmentation by Type
In terms of revenue generation, muscular dystrophy led the market segment in 2023. This can be attributed to its prevalence, especially in the pediatric population, and the high costs associated with its management, which include physiotherapy, surgical interventions, and medications. The research focus on dystrophic conditions, especially Duchenne Muscular Dystrophy (DMD), has paved the way for innovations in treatments like gene therapies and exon skipping drugs, further pushing the revenue envelope. In contrast, muscular atrophy, often a consequence of neuromuscular diseases or conditions like ALS, spinal muscular atrophy, or nerve injuries, demonstrated the highest Compound Annual Growth Rate (CAGR). The rising awareness, early diagnostic interventions, and burgeoning therapeutic pipelines for conditions like Spinal Muscular Atrophy (SMA) contribute to this growth trajectory, expected to continue from 2024 to 2032.
Market Segmentation by End-User
In 2023, hospitals emerged as the principal revenue contributor for the muscle wasting disorders market. This dominance was attributed to the comprehensive care offered, including diagnostics, therapeutics, surgeries, and rehabilitation, all under one roof. As multidisciplinary approaches became essential for managing these disorders, hospitals' holistic care model was preferred. However, from 2024 to 2032, it's expected that rehab centers will showcase the highest CAGR. As the emphasis shifts towards improving quality of life, maintaining mobility, and delaying disease progression, the role of rehabilitative therapies in muscle wasting disorders management becomes paramount. These centers, specializing in physiotherapy, occupational therapy, and speech therapy, among others, are becoming increasingly pivotal. Specialty clinics, focusing on niche therapeutic areas, and other segments like home care also play crucial roles, with patients seeking personalized, specialized care or preferring treatments within the comfort of their homes.
Market Segmentation by Region
North America, with its advanced healthcare infrastructure, research initiatives, and patient awareness, held the largest revenue share in 2023. The FDA's approval of drugs for conditions like DMD and SMA, coupled with the presence of major pharmaceutical players, propelled the region's dominance. However, the Asia-Pacific region is anticipated to exhibit the highest CAGR from 2024 to 2032. Factors like increasing healthcare expenditure, rising awareness of muscle wasting disorders, and improving diagnostic infrastructure contribute to this forecasted growth. Moreover, the burgeoning population and the presence of untapped markets present lucrative opportunities for market expansion in this region.
Competitive Trends
The muscle wasting disorders market is characterized by intense competition, with major players like Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd. leading the charge in 2023. These companies primarily focused on strategies like mergers, acquisitions, research collaborations, and aggressive R&D investments to maintain their market positions. For instance, Roche's acquisition of Spark Therapeutics accentuated its foothold in the gene therapy arena, especially concerning muscle wasting disorders. Additionally, the emphasis on patient assistance programs, ensuring drug accessibility even with high costs, became a notable strategy. Moving forward, from 2024 to 2032, it's expected that these players will continue their innovations, collaborations, and strategic alliances, driving the market forward.
Historical & Forecast Period
This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Muscle Wasting Disorders market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Muscle Wasting Disorders market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.
Market Segmentation
Type
Treatment Type
End-User
Region Segment (2022-2032; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Muscle Wasting Disorders market?
What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2032.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Muscle Wasting Disorders market?
Which is the largest regional market for Muscle Wasting Disorders market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Muscle Wasting Disorders market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Muscle Wasting Disorders market worldwide?
TABLE 3 Global Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 4 Global Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 6 Global Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 9 North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 10 North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 12 North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 15 U.S. Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 16 U.S. Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 18 U.S. Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 21 Canada Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 22 Canada Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 24 Canada Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 27 Rest of North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 28 Rest of North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 30 Rest of North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 33 UK and European Union Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 34 UK and European Union Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 36 UK and European Union Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 39 UK Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 40 UK Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 42 UK Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 45 Germany Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 46 Germany Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 48 Germany Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 51 Spain Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 52 Spain Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 54 Spain Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 57 Italy Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 58 Italy Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 60 Italy Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 63 France Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 64 France Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 66 France Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 69 Rest of Europe Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 70 Rest of Europe Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 72 Rest of Europe Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 75 Asia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 76 Asia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 78 Asia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 81 China Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 82 China Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 84 China Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 87 Japan Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 88 Japan Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 90 Japan Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 93 India Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 94 India Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 96 India Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 99 Australia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 100 Australia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 102 Australia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 105 South Korea Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 106 South Korea Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 108 South Korea Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 111 Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 112 Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 114 Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 117 Brazil Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 118 Brazil Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 120 Brazil Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 123 Mexico Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 124 Mexico Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 126 Mexico Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 129 Rest of Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 130 Rest of Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 132 Rest of Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 135 Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 136 Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 138 Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 141 GCC Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 142 GCC Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 144 GCC Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 147 Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 148 Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 150 Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
TABLE 153 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)
TABLE 154 Rest of Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)
TABLE 156 Rest of Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)
FIG. 10Market Positioning of Key Muscle Wasting Disorders Market Players, 2023
FIG. 11Global Muscle Wasting Disorders Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032